CGON · Cg Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $43.73M | - | $27.88M | $31.33M | $27.47M | - | $19.62M | $9.83M | $17.21M |
| SG&A | $20.78M | - | $23.33M | $17.41M | $14.79M | - | $8.72M | $2.49M | $5.79M |
| Total Operating Expenses | $42.26M | - | $52.80M | $48.74M | $42.26M | - | $28.34M | $12.33M | $23.00M |
| D&A | $841.0K | - | $500.0K | - | $24.0K | - | - | - | $4.0K |
| Operating Income | ($66.39M) | - | ($51.13M) | ($48.74M) | ($42.20M) | - | ($28.30M) | ($12.33M) | ($22.47M) |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($60.20M) | - | ($43.81M) | ($41.43M) | ($34.45M) | - | ($11.77M) | ($18.90M) | ($16.93M) |
| EPS - Basic | ($0.71) | - | ($0.57) | ($0.54) | ($0.45) | - | ($0.30) | ($3.93) | ($0.36) |
| EPS - Diluted | ($0.71) | - | ($0.57) | ($0.54) | ($0.45) | - | ($0.30) | ($3.93) | ($0.36) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.70M | $32.49M | $45.15M | $14.62M | $41.47M | $257.07M | $43.41M | $25.16M | $8.27M |
| Accounts Receivable | $1.27M | $688.0K | $515.0K | - | - | - | - | - | - |
| Inventory | $1.49M | $1.56M | $0 | - | - | - | - | - | - |
| Accounts Payable | $8.24M | $5.71M | $9.19M | $7.13M | $6.73M | $6.52M | $4.08M | $4.49M | $4.66M |
| Current Assets | $1.10B | $759.48M | $695.79M | $673.03M | $701.19M | $754.21M | $552.08M | $563.86M | $194.12M |
| Total Assets | $1.14B | $791.59M | $729.91M | $701.45M | $728.18M | $754.80M | $552.47M | $564.33M | $199.30M |
| Current Liabilities | $35.22M | $30.84M | $30.53M | $30.38M | $22.64M | $21.37M | $15.63M | $11.85M | $9.98M |
| Long-term Debt | $3.00M | $3.00M | $3.00M | - | - | - | - | - | - |
| Total Liabilities | $43.48M | $38.99M | $42.27M | $31.09M | $23.42M | $21.42M | $15.70M | $11.97M | $14.51M |
| Stockholders' Equity | $1.09B | $752.60M | $687.64M | $670.36M | $704.76M | $733.38M | $536.77M | $552.36M | $568.94M |
| Retained Earnings | ($439.18M) | ($378.98M) | ($337.67M) | ($293.86M) | ($252.43M) | ($217.98M) | ($186.18M) | ($165.78M) | ($129.94M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($56.94M) | - | - | - | ($29.28M) | - | - | - | ($26.01M) |
| Investing Cash Flow | ($334.85M) | - | - | - | ($186.77M) | - | - | - | ($307.44M) |
| Financing Cash Flow | $393.00M | - | - | - | $450.0K | - | - | - | $402.66M |
| CapEx | $304.0K | - | - | - | $16.0K | - | - | - | $12.0K |
| Free Cash Flow | ($57.25M) | - | - | - | ($29.29M) | - | - | - | ($26.02M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.95 | - | - | - | 0.85 | - | - | - | 1.54 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.3% | - | -6.0% | -5.9% | -4.7% | - | -2.1% | -3.3% | -8.5% |
| Return on equity | -5.5% | - | -6.4% | -6.2% | -4.9% | - | -2.2% | -3.4% | -3.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 31.30 | 24.63 | 22.79 | 22.15 | 30.97 | 35.30 | 35.32 | 47.57 | 19.44 |
| Quick ratio | 31.25 | 24.58 | 22.79 | 22.15 | 30.97 | 35.30 | 35.32 | 47.57 | 19.44 |
| Cash ratio | 0.96 | 1.05 | 1.48 | 0.48 | 1.83 | 12.03 | 2.78 | 2.12 | 0.83 |
| Leverage | |||||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
| Debt / Assets | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.04 | 1.05 | 1.06 | 1.05 | 1.03 | 1.03 | 1.03 | 1.02 | 0.35 |
| Liabilities / Assets | 0.04 | 0.05 | 0.06 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.07 |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | 5.2x | - | 4.5x | 3.0x | 2.6x | - | 4.7x | 3.8x | 3.6x |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -57.3% | - | -80.7% | -295.4% | -87.8% | - | - | - | - |
| Net income growth (YoY) | -74.7% | - | -272.3% | -119.2% | -103.5% | - | - | - | - |
| EPS growth (YoY) | -57.8% | - | -90.0% | 86.3% | -25.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -95.4% | - | - | - | -12.6% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 54.9% | 2.6% | 28.1% | 21.4% | 23.9% | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CG Oncology against the 5 most active filers in the same SIC group.